Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1058-1063

  Poppe, S M ^a   Slade, D E ^a   Chong, K T ^a   Hinshaw, R R ^a   Pagano, P J ^a   Markowitz, M ^b   Ho, D D ^b   Mo, H ^b   Gorman III, R R ^c   Dueweke, T J ^a   Thaisrivongs, S ^a   Tarpley, W G ^a  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; INDINAVIR; NELFINAVIR; PLASMA PROTEIN; PROTEINASE INHIBITOR; PYRONE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

EID: 0030895692     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1058     Document Type: Article

References (29)

1. Balzarini, J., M.-J. Perez-Perez, S. Velazquez, A. San-Felix, M.-J. Camarasa, E. DeClerq, and A. Karlsson. 1995. Suppression of the breakthrough of human immunodeficiency virus type 1 in cell culture by thiocarbonxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc. Natl. Acad. Sci. USA 92: 5470-5474.
2. Bilello, J. A., P. A. Bilello, M. Prichard, T. Robins, and G. L. Drusano. 1995. Reduction in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum α-1 acid glycoprotein. J. Infect. Dis. 171:546-551.
3. Chong, K.-T., P. J. Pagano, and R. R. Hinshaw. 1994. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′deoxythy-midine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:288-293.
4. Chou, T.-C., and P. J. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multipie drugs of enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
5. Coffin, J. M. 1095. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267:483-489.
6. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
7. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. S. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1127-1131.
8. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A novel mutation in bisheteroarylpiperazine-resistam HIV-1 reverse transcriptase confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
9. Ho, D. D., A. U. Neuman, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
10. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C.-M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C3-symmetric protease inhibitor. J. Virol. 68: 2016-2020.
11. Japour, A. A., D. L. Mayers, V. A. Johnson, D. R. Kuritakes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, The RV-43 Study Group, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibililies of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
12. Kageyama, S., B. D. Anderson, B. L. Hoesterey, H. Hayashi, Y. Kiso, K. P. Flora, and H. Mitsuya. 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38:1107-1111.
13. Kempf, D. J., et al. 1995. ABT-538 is a potent inhibitor ot human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
14. Korneyeva, M., A. Molla, D. Kempf, S. Vasavanonda, T. Chernyavskia, C. Boucher, P. Schipper, N. Lyons, Q. Gao, D. Norbeck, and J. Leonard. 1996. Clinical and virological responses to ritonavir, an inhibitor of HIV protease, abstr. Mo.B.1137. In Program and abstracts of the XI International Conference on AIDS.
15. Larder, B. A. 1995. Viral resistance and the selection of antiretroviral combinations J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:S28-S33.
16. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
17. Lazdins, J. K., et al. 1996. Effect of alpha-1-acid glycoprotein on CGP 61755. An in vitro comparative study with other relevant HIV prolease inhibitors. Abstr. 17, p. 187. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
19. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
20. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
21. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicroh. Agents Chemother. 40:292-297.
22. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P.-F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
23. Perrin, L., and S. Kinloch-deLoes. 1995. Therapeutic interventions in primary HIV infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:S69-S76.
24. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
25. Romero, D. L., M. Busso, C.-K. Tan, F. Reusser J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
26. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1996. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 4:95-107.
27. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced hy a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
28. Thaisrivongs, S., et al. 1996. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,b-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chern. 39:4349-4353.
29. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.